Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
140 hedge funds and large institutions have $932M invested in Five Prime Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 49 increasing their positions, 42 reducing their positions, and 22 closing their positions.
59% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 22
17% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 42
9% more funds holding
Funds holding: 128 → 140 (+12)
1% more capital invested
Capital invested by funds: $920M → $932M (+$12.1M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
77% less call options, than puts
Call options by funds: $2.91M | Put options by funds: $12.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$78M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$17.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.45M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.89M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$20.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.6M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$12.4M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$9.84M |
FPRX Hedge Fund Activity: Q1 2016 in Review
140 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q1 2016, worth a combined $932M — up 1.3% from $920M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new FPRX positions and 22 closed out — a net gain of 13 holders — while 49 added to existing stakes and 42 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $78M. The largest seller was Millennium Management, exiting entirely with an estimated $20.4M sold.
- 140 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q1 2016, up from 128 in Q4 2015.
- Funds reported $932M of Five Prime Therapeutics, Inc. stock for Q1 2016, up 1.3% quarter-over-quarter.
- 35 funds opened new Five Prime Therapeutics, Inc. positions in Q1 2016 and 22 closed out, a net change of +13 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q1 2016 was Fidelity Investments, an estimated $78M added.
- The largest Five Prime Therapeutics, Inc. seller in Q1 2016 was Millennium Management, an estimated $20.4M sold.
Based on aggregated 13F filings for Q1 2016.